News - Boehringer Ingelheim, Giotrif

Filter

Popular Filters

NICE draft guidance recommends Boehringer Ingelheim’s Giotrif

NICE draft guidance recommends Boehringer Ingelheim’s Giotrif

17-03-2014

UK drugs watchdog the National Institute for Health and care Excellence (NICE) this morning issued new…

Boehringer IngelheimGiotrifNorthern EuropeOncologyPharmaceuticalPricingRegulationUK

IQWiG finds that added benefit of Boehringer’s Giotrif depends on mutation status

IQWiG finds that added benefit of Boehringer’s Giotrif depends on mutation status

19-02-2014

The German Institute for Quality and Efficiency in Health Care (IQWiG), in an early benefit assessment…

Boehringer IngelheimGermanyGiotrifNorthern EuropeOncologyPharmaceuticalPricingRegulation

New data support Boehringer’s afatinib in Asian and non-Asian lung cancer patients

New data support Boehringer’s afatinib in Asian and non-Asian lung cancer patients

28-10-2013

Data from two pivotal large-scale Phase III registration studies with German independent drug major Boehringer…

afatinibBoehringer IngelheimGilotrifGiotrifOncologyPharmaceuticalResearch

Germany's Bayer and Boehringer both get CHMP backing

29-07-2013

Among a string of positive recommendations revealed last Friday (July 26) by the European Medicines Agency's…

afatinibBayerBoehringer IngelheimEuropeEyleaGiotrifOncologyOphthalmicsPharmaceuticalRegulation

Back to top